OraSure (OSUR) Q2 Revenue Falls 43%

OraSure Technologies (NASDAQ:OSUR), a diagnostics and sample collection device company, released its second quarter 2025 results on August 5, 2025. The earnings showed that GAAP revenue was $31.2 million, slightly above the $30.36 million GAAP Wall Street estimate. Non-GAAP earnings per share (EPS) stood at $(0.19), improving on the consensus estimate of $(0.21) (non-GAAP). However, this result reflected a sharp drop in GAAP revenue, which decreased 43% from the prior year and a significant swing to operating losses (GAAP). The quarter’s performance was better than expected by analysts, with both non-GAAP EPS and GAAP revenue exceeding analyst estimates, but overall financials remained pressured as the company continues to transition beyond pandemic-driven revenue peaks and adapts to a shifting funding and customer landscape.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

OraSure Technologies is known for developing and supplying rapid diagnostic tests and sample collection devices. Its portfolio includes self-tests for infectious diseases—such as the OraQuick® In-Home HIV test, the only U.S. over-the-counter oral HIV self-test—as well as tools for consumer genomics, blood and urine sample collection, and laboratory research.

Continue reading

Source Fool.com